Also lets not forget it doesnt matter continuation of trial or not be the outcome, what would matter is what the results of the interim trials were and if positive, that would be stamp of approval for the technology and should be enough to cause dramatic pps increase.
I am on board with Flipper on his commentary in prior message. Red Barron and Sitain on this board have also said many times that Germany is the "sleeping giant" and when it awakens and news rolls out it could have a significant impact on trading volume and PPS.
We have a lot of catalysts in the near horizon... all of which could have a dramatic effect on the stock. I do not believe even if we get a "continuation of the trial" that it will negatively affect the PPS in fact I think it further validates DCVax and with no safety/patient issues administering the vaccine.
DCVax and dendritic cell therapy is still working towards gaining validation in the market via trial results even though as I posted about Dr. Gorter at Medical Center Cologne adopting dendritic cell therapy over 10 years ago and showing all types of success in all different types of cancers. Dr. Gorter is using DCVax-L in the GBM trial at MCC.
I still believe there is a statistical chance progression free survival and efficacy could be strong enough from SOC to halt the trial from this terrible disease. We will find out soon enough. GLTA!
News 
Market Data 
Discover 
